Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
Cue Biopharma, Inc. (CUE), a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on February 15, 2022. The filing discloses the entry into a material definitive agreement with Silicon Valley Bank (SVB) to secure financing for its operations and clinical development.
Key Financial Metrics and Debt Structure
The Company entered into a loan and security agreement providing for term loans with an aggregate principal amount of up to $20.0 million. The filing does not provide current revenue, profit, cash flow, or margin data as this is a transactional report rather than a periodic financial statement.
- Total Facility Size: Up to $20.0 million.
- Tranche A: $10.0 million available immediately on the Effective Date.
- Tranche B: Two contingent tranches totaling up to $10.0 million, available by December 31, 2022, subject to clinical data milestones and equity financing conditions.
- Interest Rate: Floating rate equal to the greater of (Prime Rate + 2.25%) or 5.50%.
- Repayment Terms: Monthly interest payments required. Principal repayment begins June 30, 2023 (or December 31, 2023 if Tranche B is advanced). Full maturity date is December 1, 2025.
- Fees: A final payment fee of 5.00% of the original principal amount is due upon full repayment. Prepayment premiums range from 1.00% to 3.00% depending on the timing of prepayment.
- Collateral: Secured by substantially all Company properties and assets, excluding intellectual property (which is subject to a negative pledge).
Material Changes and Covenants
The primary material change is the creation of a new direct financial obligation. The agreement includes a liquidity covenant requiring the Company to maintain unrestricted and unencumbered cash at SVB equal to the lesser of all Company cash or 110% of the obligations to SVB. An event of default could trigger an interest rate increase of 3.00% and allow SVB to accelerate obligations and foreclose on collateral.
Outlook, Risks, and Contingencies
Access to the full $20.0 million facility is contingent upon specific milestones:
- Clinical Milestone: Receipt of positive data for the CUE-101 Phase 1 Part B monotherapy sufficient to begin a Phase 2 clinical trial.
- Financial Milestone: Receipt of unrestricted and unencumbered net cash proceeds from an equity securities issuance acceptable to SVB.
Risks include the potential acceleration of debt and foreclosure on assets in the event of default, as well as the obligation to pay significant fees upon repayment or prepayment.
Investor Verification Checklist
- Verify the Company's current cash balance to assess compliance with the 110% liquidity covenant.
- Monitor the status of the CUE-101 Phase 1 Part B clinical trial data to determine eligibility for Tranche B funding.
- Review upcoming equity financing plans to ensure they meet SVB's acceptance criteria for the contingent tranches.
- Calculate the total cost of capital including the 5.00% final payment fee and potential prepayment premiums.